A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women

AIDS

Volumn 28, Issue 10, 2014, Pages 1479-1487

  Nel, Annalene ^a   Haazen, Wouter ^b   Nuttall, Jeremy ^a   Romano, Joseph ^c   Rosenberg, Zeda ^a   Van Niekerk, Neliëtte ^a  

^a INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

^b SGS Life Science Services   (Belgium)

^c NWJ Group LLC   (United States)

Author keywords

Dapivirine; HIV prevention; Microbicide; Pharmacokinetics; Safety; Vaginal ring

Indexed keywords

DAPIVIRINE; PLACEBO; SILASTIC; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIMIDINE DERIVATIVE; TMC120-R147681;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DELIVERY DEVICE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROENTERITIS; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; INFESTATION; MAXIMUM TOLERATED DOSE; MEDICAL DEVICE COMPLICATION; METRORRHAGIA; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SUSTAINED DRUG RELEASE; UTERINE CERVICAL LACERATION; UTERINE CERVIX; UTERINE CERVIX DISEASE; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINA RING; VAGINAL INJURY; VAGINAL PRURITUS; VAGINAL SPECULUM; VAGINITIS; VULVA PRURITUS; VULVOVAGINAL DISCOMFORT; ADOLESCENT; BODY FLUID; CHEMISTRY; DRUG DELIVERY SYSTEM; FEMALE CONTRACEPTIVE DEVICE; VAGINA; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BODY FLUIDS; CONTRACEPTIVE DEVICES, FEMALE; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; PLACEBOS; PYRIMIDINES; VAGINA; YOUNG ADULT;

EID: 84902200641     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000280     Document Type: Article

References (21)

1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. http://www.unaids.org/globalreport/documents/ 20101123-GlobalReport-full-en.pdf.
2. UNAIDS. AIDS at 30: nations at the crossroads; 2011. http://www.unaids. org/unaids-resources/aidsat30/aids-at-30.pdf .
3. Mertenskoetter T, Kaptur PE. Update on microbicide research and development: seeking new HIV prevention tools for women. Eur J Med Res 2011; 16:1-6.
4. Keller M, Madan R, Torres N, Fazzari MJ, Cho S, Kalyoussef S, et al. A Randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PloS One 2011; 6:e16475.
5. Rosen RK, Morrow KM, Carballo-Dieguez A, Matell JE, Hoffman S, Gai F, et al. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: a mixed-methods study. J Womens Health (Larchmt) 2008; 17:383-392.
6. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006; 20:543-551.
7. Karim QA, Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
8. Das K, Clark AD Jr, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125- R165335 (etravirine) and related nonnucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004; 47:2550-2560.
9. Fletcher P, Harman S, Azijn H, Armanasco N, Manlow P, Perumal D, et al. Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2009; 53:487-495.
10. Van Herrewege Y, Michiels J, Van Roey J, Fransen K, Kestens L, Balzarini J, et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 2004; 48:337-339.
11. Di Fabio S, Van Roey J, Giannini G, Van den Mooter G, Spada M, Binelli A, et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the nonnucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 2003; 17: 1597-1604.
12. Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA, Parniak MA. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV- 1 reverse transcriptase. J Virol 1997; 71:3023-3030.
13. Nel AM, Coplan P, Smythe SC, McCord K, Mitchnick M, Kaptur PE, et al. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses 2010; 26:1181-1190.
14. Nel AM, Smythe SC, Habibi S, Kaptur PE, Romano JW. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr 2010; 55:161-169.
15. Nel AM, Coplan P, van de Wijgert JH, Kapiga SH, Von Mollendorf C, Geubbels E, et al. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 2009; 23:1531-1538.
16. Person AK, Hicks CB. Preexposure prophylaxis: one more tool for HIV prevention. Curr HIV Res 2012; 10:117-122.
17. Marrazzo J, Ramjee G, Nair G, Palenee T, Mkhize B, Nakabiito C, et al. Preexposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, March 3-6, 2013 [Abstract 26LB].
18. Romano J, Malcolm RK, Garg S, Rohan LC, Kaptur PE. Microbicide delivery: formulation technologies and strategies. Curr Opin HIV AIDS 2008; 3:558-566.
19. Romano J, Variano B, Coplan P, Van Roey J, Douville K, Rosenberg Z, et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009; 25:483-488.
20. Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg Z, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009; 51:416-423.
21. Devlin B, Nuttall J, Wilder S, Woodsong C, Rosenberg Z. Development of dapivirine vaginal ring for HIV prevention. Antiviral Research 2013; 100:S3-S8.